<i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation

Ken Takezawa, Valentina Pirazzoli, Maria E. Arcila, +13

Cancer Discovery

Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.

Takao Yamori, A. Matsunaga, Shigeo Sato, +13

PubMed

Chemoprevention StrategyMs-247 ModeHuman Cancer XenograftsCancer BiologyTumor Biology +14

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

Ken Takezawa, Isamu Okamoto, Wataru Okamoto, +7

British Journal of Cancer

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, +10

Clinical Cancer Research

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

Ken Takezawa, Isamu Okamoto, Kazuto Nishio, +2

Clinical Cancer Research

MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

Junko Tanizaki, Isamu Okamoto, Kunio Okamoto, +4

Journal of Thoracic Oncology

MedicineMetronomic TherapyPharmacologyPathologyDifferential Antitumor Effects +8

Sorafenib Inhibits Non–Small Cell Lung Cancer Cell Growth by Targeting B-RAF in <i>KRAS</i> Wild-Type Cells and C-RAF in <i>KRAS</i> Mutant Cells

Ken Takezawa, Isamu Okamoto, Kimio Yonesaka, +4

Cancer Research

Tumor BiologyOncologyOncogenic AgentCell SignalingRna Interference +13

Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for <i>EGFR</i> Mutations

Kunio Okamoto, Isamu Okamoto, Wataru Okamoto, +6

Cancer Research

Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor

Ken Takezawa, Isamu Okamoto, Junko Tanizaki, +5

Molecular Cancer Therapeutics

Gefitinib-resistant Nsclc CellsImmunologyT790m MutationCancer BiologyTumor Biology +14

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs

Tsutomu Iwasa, Isamu Okamoto, Ken Takezawa, +10

British Journal of Cancer